PARIS–(BUSINESS WIRE)–DNA Script, a global leader in enzymatic DNA synthesis (EDS) for on-demand DNA, has further strengthened its leadership team with the addition of Bruno Poddevin, Ph.D., who brings 30 years of experience in the trace manufacturing industry in the role of Senior Vice President, Business and Corporate Development.
In his new role, Poddevin will manage DNA Script’s external collaborations and partnerships, aiming for faster integration of EDS into established and innovative molecular biology and synthetic biology processes.
“DNA Script has grown significantly since its inception 8 years ago, and we are now in the next phase to become the world leader in on-demand EDSsaid Thomas Ybert, Ph.D., CEO and co-founder of DNA Script. “Business development is a strong focus and key growth driver for our business, and Bruno brings both deep and extensive experience and his established network to help us expand our market presence and execute on our growth strategies. global development.”
Poddevin has spent his professional career in the oligo industry, having held responsibilities at several pioneering DNA synthesis companies, including Genset Oligos, Proligo, Sigma-Genosys, MWG Biotech and Operon Biotechnologies. For the past 15 years, he launched and led Eurofins’ Genomics Services arm, where he helped translate DNA-based technologies into commercial applications serving a wide range of market segments including food , the environment, pharmaceutical tests and clinical genetic tests as well as the food industry. and forensic science. Poddevin holds a master’s degree in engineering and a doctorate. in molecular biology.
“In less than 10 years, EDS has reached the level of performance that chemical DNA synthesis took 50 years to achieve. Each technology iteration further improves its performance. It is clear that this technology will solve problems that traditional methods of DNA synthesis could not, opening up new avenues for the use of DNA in applications that were hitherto inaccessible, all of a more environmentally friendly way”, said Poddevine. “DNA Script is the leader in this new way of making DNA, and I am very excited to join this young and energetic team and help make this next generation of oligo synthesis widely available.
Poddevin joins DNA Script in a year where the company has seen immense growth in hiring, funding, marketing and collaborations. In early 2022, the company announced a Series C investment round of $200 million. They continued this momentum with an expansion of their global presence in Asia-Pacific and the Middle East for the sale, distribution and support of its products through distribution agreements as well as the launch of new synthesis allowing longer oligos and modifications. The company announced the continuation of collaborations with the French Defense Innovation Agency, in liaison with the General Directorate of Armaments (DGA), to detect and diagnose new pathogens, and a partnership with Wellcome Leap to accelerate the development of RNA-based products, including messenger RNA. vaccines. Recently, DNA Script received the Grand Prix Trophy at the 2022 Future French Unicorns Ceremony.
About DNA Scripting
Founded in 2014, DNA Script is a pioneering life science technology company developing a new, faster, more powerful and more versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to laboratories with the first benchtop enzyme synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life science research with innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com